Angiotensin peptide-carrier conjugates and uses thereof

Details Angiotensin peptide-carrier conjugates and uses thereof Angiotensin peptide-carrier conjugates and uses thereof

2006-10-03

2006-10-03

Mosher, Mary E. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S193100, C424S194100, C424S195110, C424S198100, C424S400000, C530S403000, C530S404000

Reexamination Certificate

active

07115266

ABSTRACT:
The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system.

REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5374426 (1994-12-01), Sabara et al.
patent: 5580589 (1996-12-01), Stoves et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5876727 (1999-03-01), Swain et al.
patent: 5935821 (1999-08-01), Chatterjee et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6380364 (2002-04-01), Mueller et al.
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2003/0175711 (2003-09-01), Renner et al.
patent: 2004/0059094 (2004-03-01), Bachmann et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2004/0076645 (2004-04-01), Bachmann et al.
patent: 2004/0136962 (2004-07-01), Renner et al.
patent: 2004/0141984 (2004-07-01), Bachmann et al.
patent: 0 201 416 (1986-04-01), None
patent: 0 259 149 (1993-12-01), None
patent: 0 578 293 (1994-01-01), None
patent: 0 385 610 (1994-03-01), None
patent: 0 465 081 (1994-04-01), None
patent: 0 283 505 (1994-07-01), None
patent: 0 425 082 (1995-04-01), None
patent: 0 421 635 (1995-07-01), None
patent: 0 677 111 (1997-05-01), None
patent: WO 92/11291 (1992-07-01), None
patent: WO 92/13081 (1992-08-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 94/15585 (1994-07-01), None
patent: WO 96/05293 (1996-02-01), None
patent: WO 96/30523 (1996-10-01), None
patent: WO 97/31948 (1997-09-01), None
patent: WO 98/15631 (1998-04-01), None
patent: WO 98/58952 (1998-12-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/28478 (1999-06-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/61054 (1999-12-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 01/62284 (2001-08-01), None
patent: WO 01/77158 (2001-10-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 01/98333 (2001-12-01), None
patent: WO 02/14478 (2002-02-01), None
Brown et al (Clinical Science 107:167-173, not prior art).
Michel (Clinical Science 107:145-147, 2004, not prior art).
Kozlovska et al (Intervirology 39:9-15, 1996).
Doggrell et al (Cardiovascular Research 39:89-105, 1998).
Chackerian et al, Proceedings of the National Academy of Sciences US 96:2373-2378, 1999.
Adhin, M.R., et al., “Nucleotide Sequence from the ssRNA Bacteriophage JP34 Resolves the Discrepancy between Serological and Biophysical Classification,”Virology 170:238-242, Academic Press, Inc. (1989).
Bachmann, M.F., and Zinkernagel, R.M., “The influence of virus structure on antibody responses and virus serotype formation,”Immunol. Today 17:553-558, Elsevier Science, Ltd. (1996).
Bachmann, M.F., and Zinkernagel, R.M., “Neutralizing Antiviral B Cell Responses,”Annu. Rev. Immunol. 15:235-270, Annual Reviews, Inc. (1997).
Biaselle, C.J., and Millar, D.B., “Studies on Triton X-100 detergent micelles,”Biophys. Chem. 3:355-361, North-Holland Publishing Company (1975).
Bullitt, E., et al., “Development of pilus organelle subassemblies in vitro depends on chaperone uncapping of a beta zipper,”Proc. Natl. Acad. Sci. USA 93:12890-12895, National Academy Press (1996).
Bullitt, E., and Makowski, L., “Bacterial Adhesion Pili Are Heterologous Assemblies of Similar Subunits,”Biophys. J. 74:623-632, Biophysical Society (1998).
Corti, M., et al., “GM1-ganglioside-Triton X-100 mixed micelles: changes of micellar properties studied by laser-light scattering and enzymatic methods,”Chem. Phys. Lipids 28:197-214, Elsevier/North-Holland Scientific Publishers, Ltd. (1981).
Coutelier, J.-P., et al., “IgG2a Restriction of murine antibodies elicited by viral infections,”J. Exp. Med. 165:64-69, The Rockefeller University Press (1987).
Davis, N.L., et al., “In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant,”Virology171:189-204, Academic Press (1989).
Eckhardt, S.G., et al., “Heptatitis B Virus Core Antigen Has Two Nuclear Localization Sequences in the Arginine-Rich Carboxyl Terminus,”J. Virol. 65:575-582, American Society for Microbiology (1991).
Eshdat, Y., et al., “Dissociation and Reassembly ofEscherichia coliType 1 Pili,”J. Bacteriol. 148:308-314, American Society for Microbiology (1981).
Fujiwara, K., et al., “Novel preparation method of immunogen for hydrophobic hapten, enzyme immunoassay for daunomycin and adriamycin,”J. Immunol. Methods 45:195-203, Elsevier/North-Holland Biomedical Press (1981).
Golomohammadi, R., et al., “The crystal structure of bacteriophage Qβ at 3.5↑ resolution,”Structure 4:543-554, Current Biology, Ltd. (1996).
Kastelein, R.A., et al., “Effect of the sequence upstream from the ribosome-binding site on the yield of protein from the cloned gene for phage MS2 coat protein,”Gene 23:245-254, Elsevier (1983).
Koschel, M., et al., “Extensive Mutagenesis of the Hepatitis B Virus Core Gene and Mapping of Mutations That Allow Capsid Formation,”J. Virol 73:2153-2160, American Society for Microbiology (1999).
Kozlovska, T.M., et al., “Recombinant RNA Qβ capsid particles synthesized and self-assembled inEscherichia coli ,” Gene 137:133-137, Elsevier Science Publishers B.V. (1993).
Kozlovskaya, T.M., et al., “Formation of capsid-like structures as a result of the expression of a cloned envelope protein gene from RNA-containing bacteriophage fr,”Dokl. Akad. Nauk. SSSR 287: 452-455, Erivan Akademiia Nauk Armianskoi Ssr (1986).
Kozlovskaya, T.M., et al., “Formation of capsid-like structures as a result of the expression of a cloned envelope protein gene from RNA-containing bacteriophage fr,” STNEasy, Accession No. 1986:219892, CAplus English abstract (1986) (Document AS6).
Liljeström, P., and Garoff, H., “A new generation of animal cell expression vectors based on the semliki forest virus replicon,”Bio/technology 9:1356-1361, Nature Publishing Company (1991).
Liljeström, P., “Alphavirus expression systems,”Curr. Opin. Biotechnol. 5:495-500, Current Biology, Ltd. (1994).
Lim, F., et al., “The RNA-binding Site of Bacteriophage Qβ Coat Protein,”J. Biol. Chem. 271:31839-31845, The American Society for Biochemistry and Molecular Biology, Inc. (1996).
Bachmann, M.F., and Zinkernagel, R.M., “Neutralizing Antiviral B Cell Responses,”Annu. Rev. Immunol. 15:235-270, Annual Reviews, Inc. (1997).
Bachmann, M.F., et al., “Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+cytotoxic T lymphocytes,”Eur. J. Immunol. 26:2595-2600, VCH Verlagsgesellschaft mbH (1996).
Borisova, G., et al., “Hybrid Hepatitis B Virus Nucleocapsid Bearing an Immunodominant Region from Hepatitis B Virus Surface Antigen,”J. Virol. 67:3696-3701, American Society fo

Affiliated with

Also associated with

Rating

Angiotensin peptide-carrier conjugates and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Angiotensin peptide-carrier conjugates and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotensin peptide-carrier conjugates and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3641745